6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period

Trial Profile

6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms EDITION-I
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Dec 2017 Results of a post-hoc analysis from EDITION 1,2, and 3 studies presented at the 2017 Congress of the International Diabetes Federation.
    • 08 Dec 2017 Results from EDITION 1,2, and 3 studies presented at the 2017 Congress of the International Diabetes Federation.
    • 08 Dec 2017 Results of post hoc analysis assessing association of HbA1c and SMPG targets in people with T2DM initiating treatment with Gla-300 using patient data from NCT01499082, NCT01499095 and NCT01676220 trials presented at the 2017 Congress of the International Diabetes Federation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top